Company intelligence / Profile preview

iCellate Medical

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

iCellate Medical is a Swedish biotech company developing liquid biopsy tests for cancer detection and biomarker analysis, primarily through its CellMate® platform. The platform isolates circulating tumor cells (CTCs) from blood, enabling genomic and protein biomarker analysis to support treatment selection. The company is currently validating its CellMate® platform in a multicenter Phase III trial for prostate cancer (METRO trial), and the platform is being tested across various cancer types[7].

Therapeutic areas: Oncology
Modalities: Liquid biopsyDiagnostic test
Industry: Molecular Diagnostics

Partnerships

Karolinska InstituteKarolinska University HospitalRoyal Institute of Technology (KTH)

Beyond the preview

Go deeper on iCellate Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCellate Medical.

Explore the full profile